Filing Details

Accession Number:
0001209191-20-035949
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-06-11 16:39:37
Reporting Period:
2020-06-09
Accepted Time:
2020-06-11 16:39:37
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1503802 Karyopharm Therapeutics Inc. KPTI () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1364719 Michael Kauffman C/O Karyopharm Therapeutics Inc.
85 Wells Avenue
Newton MA 02459
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-06-10 7,500 $4.75 562,622 No 4 M Direct
Common Stock Disposition 2020-06-10 7,500 $18.13 555,122 No 4 S Direct
Common Stock Acquisiton 2020-06-09 7,500 $4.75 763,989 No 4 M Indirect By Spouse
Common Stock Disposition 2020-06-09 7,500 $18.50 756,489 No 4 S Indirect By Spouse
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Indirect By Spouse
No 4 S Indirect By Spouse
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2020-06-10 7,500 $0.00 7,500 $4.75
Common Stock Stock Option (right to buy) Disposition 2020-06-09 7,500 $0.00 7,500 $4.75
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
341,061 2023-09-02 No 4 M Direct
385,303 2023-09-02 No 4 M Indirect
Footnotes
  1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  2. Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $18.01 to $18.23, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  3. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person.
  4. Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $18.17 to $18.83, inclusive. The spouse of the reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  5. This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on September 3, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter.